PandaOmics is a generative AI software designed for therapeutic target and biomarker discovery launched in 2020. It includes more than 20 AI and bioinformatics models, which is produced through a combination of generative AI techniques and human expert validation, and its innovative approach was first introduced in the iPANDA paper published in 2016.
PandaOmics uses in silico pathway activation network decomposition analysis and generative AI approaches to identify novel targets and biomarkers in a variety of therapeutic areas. One of the most characteristic features of PandaOmics is its knowledge graph for target-disease associations, which is generated by transformer-based natural language processing models applied to biomedical information published in scientific literature for the last 30 years. These models are a type of generative AI technology that can understand and generate human-like language. They extract relevant information from sources to create knowledge graphs that can aid in target discovery.
In March 2023, Insiico introduced ChatPandaGPT, an advanced AI chat functionality integrated into PandaOmics' knowledge graph using recent advances in large language models designed to expedite information gathering related to molecular biology, target discovery and drug development.

Chemistry42 is a customizable and fully automated software platform launched in 2020 that integrates generative AI algorithms with computational and medicinal chemistry methods to generate novel molecules with potential drug-like properties, sometimes in a matter of days.
The current version of Chemistry42 uses over 40 generative models, including generative autoencoders and generative adversarial networks. Insilico's work with generative adversarial networks was first published in 2016 in an article titled "The cornucopia of meaningful leads" in Oncotarget, and was noted in Nature Biotechnology related to the rapid identification of DDR1 kinase inhibitors.
Chemistry42 accesses both structure-based and ligand-based drug design and also has the ability to utilize predicted protein structures, such as those found in AlphaFold. Chemistry42 was designed to be seamlessly integrated with PandaOmics to enable a workflow from novel target identification to de novo small molecule generation and optimization.

InClinico is a generative AI-powered software platform utilizing a data-driven, multimodal forecast for predicting the outcome of Phase II clinical trials launched in November 2022. The platform's prediction engines utilize data from small molecule chemical properties, transcriptomics, text data and clinical trial protocols. InClinico's predictive accuracy has been tested through retrospective, quasi-prospective and prospective validation studies. InClinico's prediction engine achieved a 0.88 ROC AUC in predicting Phase II to Phase III transition in a quasi-prospective setting.
In August 2023, Insilico demonstrated that inClinico can predict the probability of success for Phase II to Phase III clinical trial transitions with a high degree of accuracy, based on multiple validation models over 7 years. The research was published in Clinical Pharmacology and Therapeutics, an authoritative cross-disciplinary journal in experimental and clinical medicine.